Try our mobile app

Switch to company model in classical logic    *

General information

Country: IRELAND

Sector: Biotechnology

Jazz Pharmaceuticals Public Limited Company is a specialty biopharmaceutical company focused on improving patients" lives by identifying, developing and commercializing innovative products that address unmet medical needs. The Company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.
Website: jazzpharma.com



Growth: Pretty weak revenue growth rate 4.1%, there is slowdown compared to average historical growth rates 18.3%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of +9.5%

Profitability: LTM EBITDA margin is positive, +24.2%. On average the margin is improving unsteadily. Gross margin is high, +74.4%. In the last quarter the company did not beat the estimated EPS, -6.8%. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 11.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 2.4% higher than minimum and 41.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.2x by EV / Sales multiple , the company can be 12.4% undervalued

Insiders: For the last 3 months insiders bought company shares on $1.0 mln (0.013% of cap.)

Key Financials (Download financials)

Ticker: JAZZ
Share price, USD:  (+0.8%)109.67
year average price 126.64  


year start price 137.93 2023-04-26

max close price 145.31 2023-08-30

min close price 107.10 2024-04-17

current price 109.67 2024-04-24
Common stocks: 62 442 504

Dividend Yield:  0.0%
FCF Yield LTM: 11.2%
EV / LTM EBITDA: 11.8x
EV / EBITDA annualized: 9.4x
Last revenue growth (y/y):  4.1%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  18.3%
Historical growth of EBITDA:  26.0%
EV / Sales: 2.9x
Margin (EBITDA LTM / Revenue): 24.2%
Fundamental value created in LTM:
Market Cap ($m): 6 848
Net Debt ($m): 4 146
EV (Enterprise Value): 10 994
Price to Book: 1.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-15Seeking Alpha

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

2024-03-29Zacks Investment Research

Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?

2024-02-29Zacks Investment Research

Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates

2024-02-28Seeking Alpha

Jazz Pharmaceuticals PLC (JAZZ) Q4 2023 Earnings Call Transcript

2024-02-28Zacks Investment Research

Here's What Key Metrics Tell Us About Jazz (JAZZ) Q4 Earnings

2024-02-28Zacks Investment Research

Jazz Pharmaceuticals (JAZZ) Q4 Earnings Lag Estimates

2024-02-23Zacks Investment Research

Exploring Analyst Estimates for Jazz (JAZZ) Q4 Earnings, Beyond Revenue and EPS

2024-02-07Proactive Investors

Redx Pharma inks $880m deal with Jazz Pharma; will bank $10m immediately

2024-01-29Seeking Alpha

Updated View On Jazz Pharmaceuticals' 2025 Goals

2024-01-03Proactive Investors

Jazz Pharmaceuticals targets positive momentum in 2024, receives Outperform rating
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-28 2023-11-08 2023-08-09 2023-05-10 2023-03-01 2022-11-09
acceptedDate 2024-02-28 16:06:20 2023-11-08 16:11:16 2023-08-09 16:10:24 2023-05-10 16:12:16 2023-03-01 16:16:47 2022-11-09 16:13:13
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 1 012M 972M 957M 893M 972M 941M
costOfRevenue 259M 102M 98M 129M 167M 134M
grossProfit 753M 870M 860M 764M 805M 807M
grossProfitRatio 0.744 0.895 0.898 0.856 0.828 0.858
researchAndDevelopmentExpenses 217M 234M 209M 189M 173M 149M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 334M 308M 341M 298M 383M 358M
otherExpenses 386M 389M 361M 150M 137M 141M
operatingExpenses 551M 698M 702M 637M 693M 649M
costAndExpenses 810M 800M 800M 766M 861M 782M
interestIncome 21M 19M 15M 0 0 0
interestExpense 90M 71M 73M 74M 74M 80M
depreciationAndAmortization 159M 163M 160M 151M 137M 149M
ebitda 361M 335M 317M 277M 249M 307M
ebitdaratio 0.357 0.345 0.331 0.310 0.256 0.327
operatingIncome 202M 172M 158M 126M 112M 158M
operatingIncomeRatio 0.200 0.177 0.165 0.141 0.115 0.168
totalOtherIncomeExpensesNet -141M -1M -2M -71M -452M -219M
incomeBeforeTax 62M 100M 82M 55M -340M -60M
incomeBeforeTaxRatio 0.061 0.102 0.085 0.062 -0.350 -0.064
incomeTaxExpense -33M -47M -24M -15M -100M -43M
netIncome 94M 147M 104M 69M -240M -17M
netIncomeRatio 0.093 0.151 0.109 0.078 -0.247 -0.018
eps 1.500 2.330 1.630 1.090 -3.810 -0.270
epsdiluted 1.350 2.060 1.520 1.040 -3.810 -0.270
weightedAverageShsOut 63M 63M 74M 63M 63M 63M
weightedAverageShsOutDil 70M 71M 74M 74M 63M 63M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-28 2023-11-08 2023-08-09 2023-05-10 2023-03-01 2022-11-09
acceptedDate 2024-02-28 16:06:20 2023-11-08 16:11:16 2023-08-09 16:10:24 2023-05-10 16:12:16 2023-03-01 16:16:47 2022-11-09 16:13:13
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 1 206M 1 336M 1 282M 1 168M 881M 839M
shortTermInvestments 420M 250M 80M 0 0 60M
cashAndShortTermInvestments 1 626M 1 586M 1 362M 1 168M 881M 899M
netReceivables 706M 628M 610M 624M 651M 601M
inventory 597M 612M 657M 675M 714M 728M
otherCurrentAssets 335M 101M 73M 245M 267M 45M
totalCurrentAssets 3 264M 3 246M 3 010M 2 785M 2 606M 2 572M
propertyPlantEquipmentNet 235M 288M 298M 303M 301M 290M
goodwill 1 753M 1 705M 1 743M 1 723M 1 693M 1 593M
intangibleAssets 5 418M 5 418M 5 706M 5 764M 5 794M 5 570M
goodwillAndIntangibleAssets 7 171M 7 123M 7 448M 7 488M 7 487M 7 163M
longTermInvestments 5M 7M 8M 0 0 0
taxAssets 478M 464M 430M 399M 376M 315M
otherNonCurrentAssets 241M 76M 66M 73M 64M 45M
totalNonCurrentAssets 8 129M 7 958M 8 251M 8 262M 8 229M 7 813M
otherAssets 0 0 0 0 0 0
totalAssets 11 393M 11 204M 11 261M 11 047M 10 835M 10 385M
accountPayables 103M 110M 98M 125M 91M 102M
shortTermDebt 624M 621M 48M 31M 31M 46M
taxPayables 35M 89M 68M 40M 8M 10M
deferredRevenue 35M 4000.000 4000.000 4000.000 463 000 871 000
otherCurrentLiabilities 774M 842M 799M 752M 811M 664M
totalCurrentLiabilities 1 537M 1 573M 945M 909M 933M 813M
longTermDebt 5 108M 5 173M 5 752M 5 762M 5 765M 5 769M
deferredRevenueNonCurrent 64M 0 0 0 0 116 000
deferredTaxLiabilitiesNonCurrent 848M 841M 911M 932M 944M 934M
otherNonCurrentLiabilities 100M 127M 127M 109M 107M 6 678M
totalNonCurrentLiabilities 6 120M 6 141M 6 790M 6 803M 6 816M 6 827M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 64M 79M 83M 72M 72M 88M
totalLiabilities 7 656M 7 715M 7 735M 7 712M 7 750M 7 639M
preferredStock 0 0 0 0 0 0
commonStock 61 000 61 000 61 000 61 000 61 000 61 000
retainedEarnings 879M 884M 812M 803M 734M 974M
accumulatedOtherComprehensiveIncomeLoss -842M -1 035M -867M -980M -1 126M -1 618M
othertotalStockholdersEquity 3 700M 3 640M 3 581M 3 512M 3 478M 3 388M
totalStockholdersEquity 3 737M 3 489M 3 526M 3 335M 3 086M 2 745M
totalEquity 3 737M 3 489M 3 526M 3 335M 3 086M 2 745M
totalLiabilitiesAndStockholdersEquity 11 393M 11 204M 11 261M 11 047M 10 835M 10 385M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 11 393M 11 204M 11 261M 11 047M 10 835M 10 385M
totalInvestments 425M 250M 80M 0 0 60M
totalDebt 5 797M 5 794M 5 800M 5 793M 5 796M 5 815M
netDebt 4 590M 4 458M 4 518M 4 625M 4 915M 4 975M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol JAZZ JAZZ JAZZ JAZZ JAZZ JAZZ
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-28 2023-11-08 2023-08-09 2023-05-10 2023-03-01 2022-11-09
acceptedDate 2024-02-28 16:06:20 2023-11-08 16:11:16 2023-08-09 16:10:24 2023-05-10 16:12:16 2023-03-01 16:16:47 2022-11-09 16:13:13
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 94M 147M 104M 69M -241M -20M
depreciationAndAmortization 159M 163M 160M 157M 145M 149M
deferredIncomeTax -36M -79M -79M -66M -145M -65M
stockBasedCompensation 53M 56M 61M 56M 62M 57M
changeInWorkingCapital -181M -25M -17M 18M 59M 70M
accountsReceivables -75M -19M 14M 28M -46M -10M
inventory -1M -5M -816 000 -6M 816 000 -9M
accountsPayables -8M 10M -27M 34M -15M 29M
otherWorkingCapital -96M -11M -4M -38M 120M 59M
otherNonCashItems 78M 45M 68M 85M 463M 227M
netCashProvidedByOperatingActivities 167M 307M 297M 321M 342M 418M
investmentsInPropertyPlantAndEquipment -10M -4M -6M -5M -384M 5M
acquisitionsNet 0 -20M 0 0 0 0
purchasesOfInvestments -120M -190M -80M 0 61M -300 000
salesMaturitiesOfInvestments 250M 20M 0 0 60M 0
otherInvestingActivites -18M 20M 0 0 -61M 0
netCashUsedForInvestingActivites 102M -174M -86M -5M -324M 5M
debtRepayment -8M -8M -8M -8M -8M -308M
commonStockIssued 9M 6M 11M 0 0 0
commonStockRepurchased -100M -74M -96M 0 0 0
dividendsPaid 0 -6M -85M 0 0 0
otherFinancingActivites -2M 4M 81M -22M 27M 19M
netCashUsedProvidedByFinancingActivities -100M -78M -97M -30M 20M -289M
effectOfForexChangesOnCash 2M -1M 34 000 331 000 5M -5M
netChangeInCash 181M 53M 114M 286M 42M 128M
cashAtEndOfPeriod 1 206M 1 336M 1 282M 1 168M 881M 839M
cashAtBeginningOfPeriod 1 026M 1 282M 1 168M 881M 839M 711M
operatingCashFlow 167M 307M 297M 321M 342M 418M
capitalExpenditure -10M -4M -6M -5M -384M 5M
freeCashFlow 157M 303M 291M 316M -42M 423M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-09 ET (fiscal 2023 q2)
2023 q1
2023-05-10 ET (fiscal 2023 q1)
2022 q4
2023-03-01 ET (fiscal 2022 q4)
2022 q3
2022-11-09 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-28 21:05 ET
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
2024-02-27 12:45 ET
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
2024-02-21 12:45 ET
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
2024-02-20 21:15 ET
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
2024-02-14 21:15 ET
Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024
2024-02-08 11:47 ET
Redx Pharma lands biggest deal to date with sale of KRAS inhibitor programme to Jazz Pharma
2024-02-07 07:00 ET
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program
2023-12-21 21:05 ET
Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder
2023-12-20 21:15 ET
Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-08 18:20 ET
Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer
2023-12-01 14:02 ET
Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
2023-11-30 12:45 ET
Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings
2023-11-14 07:00 ET
Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
2023-11-08 21:05 ET
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
2023-11-07 12:45 ET
Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers
2023-11-01 20:15 ET
Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
2023-10-25 20:15 ET
Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023
2023-10-23 11:45 ET
Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adul...
2023-10-18 11:45 ET
Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023
2023-10-16 11:45 ET
Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023
2023-09-21 21:41 ET
Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
2023-09-13 20:15 ET
Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences
2023-09-12 11:30 ET
Jazz Pharmaceuticals Announces Key Update to Leadership Team
2023-09-11 11:45 ET
Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023
2023-08-24 20:23 ET
Jazz Pharmaceuticals to Participate in Citi's 18th Annual BioPharma Conference
2023-08-09 20:05 ET
Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance
2023-07-26 20:15 ET
Jazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023
2023-07-21 12:08 ET
Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
2023-06-02 22:41 ET
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
2023-05-31 11:45 ET
Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023
2023-05-30 20:15 ET
Jazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare Conference
2023-05-25 20:15 ET
Jazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023
2023-05-10 20:05 ET
Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance
2023-05-02 20:15 ET
Jazz Pharmaceuticals to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
2023-04-27 11:30 ET
Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023
2023-04-26 20:15 ET
Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023
2023-04-19 11:45 ET
Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting
2023-03-30 11:44 ET
Jazz Pharmaceuticals Expands Support of the American Heart Association to Raise Awareness of the Link Between Sleep Disorders and Heart Health
2023-03-15 11:00 ET
Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline
2023-03-01 21:05 ET
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance
2023-02-27 21:15 ET
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
2023-02-15 21:15 ET
Jazz Pharmaceuticals to Report 2022 Fourth Quarter and Full Year Financial Results on March 1, 2023
2023-01-19 12:45 ET
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
2023-01-03 12:30 ET
Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-21 12:30 ET
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
2022-12-05 13:00 ET
Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies
2022-11-28 13:09 ET
Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes at the 2022 American Epilepsy Society Annual Meeting
2022-11-18 18:00 ET
Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn)
2022-11-14 14:00 ET
STAND UP TO CANCER LAUNCHES NEW RADIO PSA WITH JAZZ PHARMACEUTICALS TO ENCOURAGE LUNG CANCER SCREENING
2022-11-09 21:05 ET
Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point
2022-11-03 14:43 ET
Jazz Pharmaceuticals to Present Data at 2022 ASH Meeting Showcasing Commitment to Advancing Oncology Research
2022-11-01 20:15 ET
Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
2022-10-26 20:15 ET
Jazz Pharmaceuticals to Report 2022 Third Quarter Financial Results on November 9, 2022
2022-10-19 10:07 ET
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
2022-10-19 10:00 ET
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
2022-09-15 20:30 ET
Jazz Pharmaceuticals to Present Advancements in Sleep Medicine at Psych Congress 2022
2022-08-31 20:15 ET
Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
2022-08-18 11:30 ET
Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex®/Epidyolex® (cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures
2022-08-03 20:05 ET
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
2022-07-20 20:15 ET
Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022
2022-06-28 11:30 ET
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity
2022-06-07 11:30 ET
Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting
2022-06-01 20:15 ET
Jazz Pharmaceuticals to Participate in the Jefferies Healthcare Conference
2022-06-01 11:45 ET
Jazz Pharmaceuticals to Present New Data at SLEEP 2022 Reinforcing Leadership in Sleep Medicine
2022-05-12 15:57 ET
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings
2022-05-04 20:10 ET
Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance
2022-05-04 20:05 ET
Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist
2022-05-03 20:15 ET
Jazz Pharmaceuticals to Participate in the BofA Securities 2022 Global Healthcare Conference
2022-04-20 20:15 ET
Jazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022
2022-04-08 17:00 ET
Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types
2022-03-29 20:15 ET
Jazz Pharmaceuticals to Participate in Upcoming April Investor Conferences
2022-03-25 07:00 ET
Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing
2022-03-24 11:30 ET
Jazz Pharmaceuticals Announces First Patient Enrolled in EMERGE-201 Phase 2 Basket Trial Evaluating Zepzelca® (lurbinectedin) Monotherapy in Patients with Select Advanced or Metastatic Solid Tumors
2022-03-08 21:35 ET
Jazz Pharmaceuticals to Present Pan-RAF Inhibitor Pre-Clinical Data at American Association for Cancer Research (AACR) 2022 Annual Meeting
2022-03-01 21:05 ET
JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS
2022-02-28 21:15 ET
Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
2022-02-15 21:15 ET
Jazz Pharmaceuticals to Report 2021 Fourth Quarter and Full Year Financial Results on March 1, 2022
2022-02-02 12:30 ET
Jazz Pharmaceuticals Completes U.S. FDA Supplemental Biologics License Application for Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Monday/Wednesday/Friday Dosing Schedule
2022-01-10 12:30 ET
Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader
2022-01-05 12:45 ET
Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia
2022-01-03 21:15 ET
Jazz Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
2022-01-03 21:10 ET
U.S. FDA Grants Orphan Drug Exclusivity (ODE) for Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults
2021-12-30 12:45 ET
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating JZP150 for Once-Daily Treatment of Adults with Post-Traumatic Stress Disorder
2021-12-15 12:45 ET
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor
2021-12-13 07:30 ET
PharmaMar and Jazz Pharmaceuticals Announce Initiation of Confirmatory Phase 3 Clinical Trial of Zepzelca® (lurbinectedin) for the Treatment of Patients with Relapsed Small Cell Lung Cancer
2021-12-12 14:00 ET
Jazz Pharmaceuticals Presents Positive Interim Phase 2/3 Results of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at ASH 2021 Annual Meeting
2021-12-01 12:45 ET
Jazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex® (cannabidiol) Oral Solution Data at the 2021 American Epilepsy Society Annual Meeting
2021-11-30 13:00 ET
Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluating Zepzelca® (lurbinectedin) in Combination with a PD-L1 Inhibitor in Small Cell Lung Cancer
2021-11-09 21:15 ET
Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences
2021-11-09 21:05 ET
Jazz Pharmaceuticals Announces Third Quarter 2021 Financial Results And Raises Full Year Earnings Guidance
2021-11-04 15:04 ET
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advances Across Hematology/Oncology at ASH 2021 Annual Meeting
2021-10-26 20:15 ET
Jazz Pharmaceuticals to Report 2021 Third Quarter Financial Results on November 9, 2021
2021-09-13 20:15 ET
Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021
2021-09-08 20:15 ET
Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
2021-08-12 18:30 ET
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults
2021-08-10 12:00 ET
Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers
2021-08-10 08:24 ET
GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex
2021-08-03 20:05 ET
Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results
2021-07-29 08:00 ET
Onera raises €10.5M in Series B funding
2021-07-22 20:15 ET
National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia
2021-07-20 20:15 ET
Jazz Pharmaceuticals to Report 2021 Second Quarter Financial Results on August 3, 2021
2021-07-13 20:15 ET
Jazz Pharmaceuticals Announces Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021
2021-07-01 00:04 ET
Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
2021-06-25 11:45 ET
Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution
2021-06-17 11:30 ET
Jazz Pharmaceuticals Updates 2021 Financial Guidance to Include Recently Acquired GW Pharmaceuticals plc
2021-06-14 11:30 ET
Jazz Pharmaceuticals and Leading Cancer Organizations Collaborate to Launch First and Only Digital Hub Focused Exclusively on Emotional, Social and Physical Health Needs of Small Cell Lung Cancer Community
2021-06-09 11:45 ET
Jazz Pharmaceuticals Presents 18 Abstracts in Sleep Medicine at SLEEP 2021
2021-05-26 20:15 ET
Jazz Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference on June 2, 2021
2021-05-20 11:45 ET
Jazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio
2021-05-10 10:30 ET
Bionical Emas launches Expanded Access Program for JZP458 - a recombinant Erwinia Asparaginase
2021-05-05 13:15 ET
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc
2021-05-04 20:15 ET
Jazz Pharmaceuticals to Participate in Three Investor Conferences in May 2021
2021-05-04 20:05 ET
Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results
2021-04-29 20:05 ET
Jazz Pharmaceuticals Announces Closing of Senior Secured Notes Offering
2021-04-23 20:01 ET
GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals
2021-04-22 21:01 ET
Jazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes Offering
2021-04-20 12:45 ET
Jazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured Notes
2021-04-20 11:45 ET
Jazz Pharmaceuticals Presents Phase 3 Study Results of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academy of Neurology Annual Meeting
2021-04-19 20:05 ET
Jazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021
2021-04-12 11:45 ET
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic Hypersomnia
2021-04-05 10:00 ET
Oyster Point Pharma Announces New Appointment to Board of Directors
2021-03-30 22:15 ET
Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients
2021-03-22 20:05 ET
Jazz Pharmaceuticals Announces Participation at the 10th Annual J.P. Morgan Napa Valley Forum
2021-03-18 11:45 ET
Jazz Pharmaceuticals and Hypersomnia Foundation Launch Campaign to Increase Understanding and Awareness of Idiopathic Hypersomnia
2021-02-23 21:10 ET
Jazz Pharmaceuticals Announces Participation at Cowen 41st Annual Healthcare Conference
2021-02-23 21:05 ET
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results
2021-02-17 21:05 ET
Jazz Pharmaceuticals Announces Participation in the Leerink 10th Annual Global Healthcare Conference
2021-02-16 12:45 ET
Jazz Pharmaceuticals Completes Submission of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia
2021-02-09 21:05 ET
Jazz Pharmaceuticals to Report 2020 Fourth Quarter Financial Results on February 23, 2021
2021-02-09 13:30 ET
Lexaria Outlook is Promising After Jazz Acquisition of GW
2021-02-03 12:30 ET
Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader
2021-01-04 21:05 ET
Jazz Pharmaceuticals Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference
2020-12-21 13:00 ET
Jazz Pharmaceuticals Announces Initiation of Biologics License Application Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
2020-12-03 07:00 ET
Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca™ in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line
2020-11-17 12:30 ET
Jazz Pharmaceuticals Appoints Jennifer Cook and Mark Smith, M.D. to its Board of Directors
2020-11-10 21:05 ET
Jazz Pharmaceuticals Announces Participation at Jefferies Virtual London Healthcare Conference
2020-11-05 12:30 ET
Data at ASH 2020 Annual Meeting Highlights Jazz Pharmaceuticals' Commitment to Advancing Hematology/Oncology Research
2020-11-02 21:05 ET
Jazz Pharmaceuticals Announces Third Quarter 2020 Financial Results
2020-10-26 11:30 ET
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
2020-10-20 11:30 ET
Jazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients with Narcolepsy
2020-10-19 20:15 ET
Jazz Pharmaceuticals Announces Webcast for Xywav Investor Update
2020-10-19 20:05 ET
Jazz Pharmaceuticals to Report 2020 Third Quarter Financial Results on November 2, 2020
2020-10-14 20:05 ET
New Data for Zepzelca™ (lurbinectedin) to be Presented at IASLC 2020 North America Conference on Lung Cancer
2020-10-08 11:30 ET
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia
2020-09-17 11:00 ET
Jazz Pharmaceuticals Launches Initiative to Help Educate People Living with Rare Form of Leukemia
2020-09-15 12:00 ET
Jazz Pharmaceuticals Announces New Sleep Health Collaboration
2020-09-09 11:30 ET
Jazz Pharmaceuticals Announces New Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies
2020-09-08 20:05 ET
Jazz Pharmaceuticals Announces Participation at Three Upcoming Virtual Investor Conferences
2020-08-27 12:00 ET
Jazz Pharmaceuticals to Present New Data on Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Sunosi® (solriamfetol) at Virtual SLEEP 2020
2020-08-04 20:05 ET
Jazz Pharmaceuticals Announces Second Quarter 2020 Financial Results
2020-07-22 11:30 ET
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
2020-07-21 20:05 ET
Jazz Pharmaceuticals to Report 2020 Second Quarter Financial Results on August 4, 2020
2020-07-13 12:00 ET
National Comprehensive Cancer Network® adds Zepzelca™ (lurbinectedin) to Clinical Practice Guidelines in Oncology
2020-06-15 19:35 ET
Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer
2020-06-09 11:00 ET
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 2.000% Exchangeable Senior Notes due 2026
2020-06-08 11:00 ET
Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2026
2020-05-27 20:05 ET
Jazz Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
2020-05-14 13:53 ET
Jazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 Meetings
2020-05-11 12:30 ET
Jazz Pharmaceuticals Announces Appointment Of Kim Sablich As Executive Vice President, General Manager Of North America
2020-05-11 12:30 ET
Bionical Emas and Jazz Pharmaceuticals Enter into an Agreement for Expanded Access to Lurbinectedin in Relapsed Small Cell Lung Cancer in the United States
2020-05-06 20:05 ET
Jazz Pharmaceuticals Announces Participation at Upcoming Virtual Investor Conferences
2020-05-05 20:05 ET
Jazz Pharmaceuticals Announces First Quarter 2020 Financial Results
2020-04-29 20:05 ET
Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease
2020-04-21 20:05 ET
Jazz Pharmaceuticals to Report 2020 First Quarter Financial Results on May 5, 2020
2020-03-31 20:01 ET
Jazz Pharmaceuticals Provides COVID-19 Business Update
2020-03-25 20:05 ET
Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
2020-02-26 21:05 ET
Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences
2020-02-25 21:05 ET
Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2019 Financial Results
2020-02-17 07:30 ET
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
2020-02-11 21:05 ET
Jazz Pharmaceuticals to Report 2019 Fourth Quarter and Full Year Financial Results on February 25, 2020
2020-01-22 13:00 ET
Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy
2020-01-22 07:30 ET
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
2020-01-20 15:35 ET
Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
2020-01-06 21:05 ET
Jazz Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-11-15 11:45 ET
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
2019-11-14 21:05 ET
Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences
2019-11-07 13:00 ET
Jazz Pharmaceuticals to Highlight Growing Hematology Oncology Pipeline at ASH 2019 Annual Meeting
2019-11-05 21:05 ET
Jazz Pharmaceuticals Announces Third Quarter 2019 Financial Results
2019-10-22 20:05 ET
Jazz Pharmaceuticals to Report 2019 Third Quarter Financial Results on November 5, 2019
2019-10-10 20:15 ET
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of CAR-T Associated Neurotoxicity
2019-09-30 12:30 ET
Jazz Pharmaceuticals Survey Highlights Prevalence of Misinformation and Misperception About Narcolepsy Among Americans
2019-09-18 20:05 ET
Jazz Pharmaceuticals Announces Webcast for World Sleep Congress Investor Update
2019-08-27 20:05 ET
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
2019-08-12 20:01 ET
Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.
2019-08-06 20:01 ET
Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program
2019-07-23 20:05 ET
Jazz Pharmaceuticals to Report 2019 Second Quarter Financial Results on August 6, 2019
2019-07-10 06:00 ET
Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma
2019-06-25 20:05 ET
Jazz Pharmaceuticals Announces Webcast for Sunosi Investor Update
2019-06-17 12:00 ET
Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi(TM) (solriamfetol)
2019-05-16 20:30 ET
Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress
2019-04-23 20:05 ET
Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019

SEC forms

Show financial reports only

SEC form 10
2024-02-28 17:03 ET
Jazz Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-28 16:06 ET
Jazz Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-28 16:06 ET
Jazz Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Jazz Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Jazz Pharmaceuticals published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Jazz Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-08 16:11 ET
Jazz Pharmaceuticals reported for 2023 q3
SEC form 8
2023-11-08 16:07 ET
Jazz Pharmaceuticals published news for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Jazz Pharmaceuticals published news for 2023 q3
SEC form 10
2023-08-09 16:10 ET
Jazz Pharmaceuticals reported for 2023 q2
SEC form 6
2023-08-09 16:07 ET
Jazz Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Jazz Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Jazz Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-22 16:05 ET
Jazz Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Jazz Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-10 00:00 ET
Jazz Pharmaceuticals published news for 2023 q1
SEC form 10
2023-03-01 16:16 ET
Jazz Pharmaceuticals reported for 2022 q4
SEC form 6
2023-03-01 16:07 ET
Jazz Pharmaceuticals published news for 2022 q4
SEC form 10
2023-03-01 00:00 ET
Jazz Pharmaceuticals reported for 2022 q4
SEC form 8
2023-03-01 00:00 ET
Jazz Pharmaceuticals reported for 2022 q4
SEC form 6
2023-01-09 07:31 ET
Jazz Pharmaceuticals published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Jazz Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-04 17:25 ET
Jazz Pharmaceuticals published news for 2022 q4
SEC form 6
2022-12-21 07:40 ET
Jazz Pharmaceuticals published news for 2022 q3
SEC form 6
2022-12-05 16:16 ET
Jazz Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-14 16:31 ET
Jazz Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-09 16:13 ET
Jazz Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-09 16:07 ET
Jazz Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-09 00:00 ET
Jazz Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Jazz Pharmaceuticals reported for 2022 q3
SEC form 6
2022-10-19 06:59 ET
Jazz Pharmaceuticals published news for 2022 q3
SEC form 10
2022-08-03 16:22 ET
Jazz Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-03 16:07 ET
Jazz Pharmaceuticals published news for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Jazz Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Jazz Pharmaceuticals reported for 2022 q2
SEC form 6
2022-06-10 20:04 ET
Jazz Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-31 16:43 ET
Jazz Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-04 16:20 ET
Jazz Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-04 16:17 ET
Jazz Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-04 16:13 ET
Jazz Pharmaceuticals published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Jazz Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Jazz Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-02 16:30 ET
Jazz Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-07 07:15 ET
Jazz Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-28 08:55 ET
Jazz Pharmaceuticals published news for 2021 q4
SEC form 10
2022-03-01 16:17 ET
Jazz Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-01 16:07 ET
Jazz Pharmaceuticals published news for 2021 q4
SEC form 8
2022-03-01 00:00 ET
Jazz Pharmaceuticals published news for 2021 q4
SEC form 10
2022-03-01 00:00 ET
Jazz Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-10 07:47 ET
Jazz Pharmaceuticals published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Jazz Pharmaceuticals published news for 2021 q4
SEC form 10
2021-11-09 16:12 ET
Jazz Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-09 16:07 ET
Jazz Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Jazz Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Jazz Pharmaceuticals published news for 2021 q3
SEC form 6
2021-09-23 20:10 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-30 10:09 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-19 17:07 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-03 16:37 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-03 16:07 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-03 00:00 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-03 00:00 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-28 20:16 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-19 16:03 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-01 17:17 ET
Jazz Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-11 16:38 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-01 16:16 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-05 16:10 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-04 16:45 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-04 16:08 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-04 00:00 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-29 16:23 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-23 16:40 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-23 16:26 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-22 17:08 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-20 09:01 ET
Jazz Pharmaceuticals published news for 2021 q1
SEC form 6
2021-03-23 16:33 ET
Jazz Pharmaceuticals published news for 2020 q4
SEC form 6
2021-03-22 06:36 ET
Jazz Pharmaceuticals published news for 2020 q4
SEC form 10
2021-02-23 16:48 ET
Jazz Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 16:08 ET
Jazz Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-03 18:41 ET
Jazz Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-03 07:52 ET
Jazz Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-12 16:22 ET
Jazz Pharmaceuticals published news for 2020 q4
SEC form 6
2020-11-17 07:36 ET
Jazz Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-02 16:48 ET
Jazz Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-02 16:11 ET
Jazz Pharmaceuticals published news for 2020 q3